Abstract
Background Alexander disease is a rare neurological ailment caused by the degeneration of the white matter of the brain accompanied with the formation of Rosenthal fibers, a unique cytoplasmic inclusion within astrocytes (non-nerve tissue) in the brain. Till to date only heterozygous de novo mutation in Glial Fibrillary Acidic Protein (GFAP) gene is found to be associated for the disease phenotype.
Methods and Result the aim of our study was to determine the genetic basis of an Indian-origin juvenile AxD patient with pathological symptoms of macrocephaly and psychomotor delay followed by regression, spastic parapresis and feeding difficulty. The patient was screened for mutation in candidate gene for AxD by Whole Exome Sequencing and the detected variants were further reconfirmed by Sanger sequencing. The clonicopathological feature were investigated and two heterozygous missence variants (c.983T>C and c. 626G>A) were indentify in GFAP gene of the patient. Familial screenings of both of these variants were predicted to be pathogenic or damaging by various in silico methods and prediction tools.
Conclusion This altered GFA protein get accumulated in cytoplasm of the astroglial cells, leading to formation of Rosenthal fibers, which impairs cell function. Future study, however, would be helpful to understand the functional mechanism of these variant in formation of Rosenthal fibers leading to AxD pathophysiology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee, Institute of Science, Banaras Hindu University, Varanasi, Ref No. I.Sc./ECM-XII/2021-22 Ethics committee, Institute of science, Banaras Hindu University, Varanasi, Uttar Pradesh, Ref No. I.Sc./ECM-XII/2021-22
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript
